(firstQuint)Pemetrexed/Cisplatin Intercalating Gefitinib Treating EGFR Wild NSCLC.

 In preclinical data, it is identified that pemetrexed combined with erlotinib could achieve good response than pemetrexed because EGFR-TKI (erlotinib) could enhance the sensitivity of pemetrexed.

 So we design the trial to investigate curative effect between Pemetrexed/Cisplatin and Pemetrexed/Cisplatin intercalating Gefitinib Treating EGFR Wild NSCLC.

.

 Pemetrexed/Cisplatin Intercalating Gefitinib Treating EGFR Wild NSCLC@highlight

To investigate the curative effect between Pemetrexed/Cisplatin and Pemetrexed/Cisplatin intercalating Gefitinib Treating EGFR Wild NSCLC